drugset / Trial / NCT06111846
Study of Human Bone Marrow Mesenchymal Stem Cells in APAP
Phase 2
Active not recruiting
10 enrolled
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
The First Affiliated Hospital of Guangzhou Medical University · collab
NaSequentialOpen-labelTreatment
Summary
The purpose of this open-label phase IIa clinical trial study is to evaluate the safety and preliminary efficacy of hBMMSC intravenous treatment in patients with aPAP.
Timeline
- Start
- 2023-12-25
- Primary completion
- 2025-07-22
- Completion
- 2026-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donor-derived Mesenchymal Stromal Cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | Donor-derived Mesenchymal Stromal Cells | Cell therapy | 2e+06 cells/kg | Intravenous |